CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading researcher profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Researchers/Profile

Researcher profile

Mary Kathryn Dahlgren

OPENALEX: A5087811308↗ORCID: 0000-0003-0706-531X↗

Affiliations

Organizations

Cognitive Neuroimaging Labauthorship · FR Harvard Universityauthorship · US McLean Hospitalauthorship · US

Public evidence

3 connected articles

Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study.2025 · Europe PMC Increased White Matter Coherence Following Three and Six Months of Medical Cannabis Treatment.2022 · PubMed Central Open Access Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial.2022 · PubMed Central Open Access

Matched by exact identifiers only. Profile data: Corpus/OpenAlex.

Mary Kathryn Dahlgren - Medical Cannabis Research Engine